Cyclacel Pharmaceuticals (NASDAQ:CYCC) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Cyclacel Pharmaceuticals (NASDAQ:CYCC) posted its earnings results on Wednesday. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04), Zacks reports. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ CYCC opened at $0.25 on Thursday. Cyclacel Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $4.00. The stock’s 50-day simple moving average is $0.33 and its 200-day simple moving average is $0.50. The firm has a market cap of $1.54 million, a price-to-earnings ratio of -0.03 and a beta of 0.28.

Insider Activity at Cyclacel Pharmaceuticals

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 23.97% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals in a research note on Monday. They set a “sell” rating on the stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.